Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis

被引：138

作者：

Chuzi, Sarah ^{[1
]}

Tavora, Fabio ^{[2
]}

Cruz, Marcelo ^{[3
]}

Costa, Ricardo ^{[3
]}

Chae, Young Kwang ^{[3
]}

Carneiro, Benedito A. ^{[3
]}

Giles, Francis J. ^{[3
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Dept Med, 251 East Huron St,Galter Suite 3-150, Chicago, IL 60611 USA

[2] Messejana Heart & Lung Hosp, Argos Lab, Fortaleza, Ceara, Brazil

[3] Northwestern Univ, Div Hematol Oncol, Feinberg Sch Med, Dev Therapeut Program, Chicago, IL 60611 USA

来源：

CANCER MANAGEMENT AND RESEARCH | 2017年 / 9卷

关键词：

immune checkpoint inhibitors; pneumonitis; anti-PD-1; anti-CTLA-4; immune-related adverse event; CELL LUNG-CANCER; LONG-TERM SAFETY; ADVANCED MELANOMA; UNTREATED MELANOMA; ADVERSE EVENTS; OPEN-LABEL; INTERSTITIAL PNEUMONITIS; METASTATIC MELANOMA; PHASE-2; TRIAL; ANTIBODY;

D O I：

10.2147/CMAR.S136818

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Immune checkpoint inhibitors, including cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) inhibitors, represent an effective treatment modality for multiple malignancies. Despite the exciting clinical benefits, checkpoint inhibition is associated with a series of immune-related adverse events (irAEs), many of which can be life-threatening and result in significant treatment delays. Pneumonitis is an adverse event of special interest as it led to treatment-related deaths in early clinical trials. This review summarizes the incidence of pneumonitis during treatment with the different checkpoint inhibitors and discusses the prognostic significance of tumor type. The wide range of clinical, radiographic, and histologic characteristics of checkpoint inhibitor-related pneumonitis is reviewed and followed by guidance on the different management strategies.

引用

页码：207 / 213

页数：7

共 51 条

[1]

Organizing Pneumonia as a Side Effect of Ipilimumab Treatment of Melanoma [J].

Barjaktarevic, Igor Z. ;

Qadir, Nida ;

Suri, Anu ;

Santamauro, Jean T. ;

Stover, Diane .

CHEST, 2013, 143 (03) :858-861

[2]

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation [J].

Bashey, Asad ;

Medina, Bridget ;

Corringham, Sue ;

Pasek, Mildred ;

Carrier, Ewa ;

Vrooman, Linda ;

Lowy, Israel ;

Solomon, Scott R. ;

Morris, Lawrence E. ;

Holland, H. Kent ;

Mason, James R. ;

Alyea, Edwin P. ;

Soiffer, Robert J. ;

Ball, Edward D. .

BLOOD, 2009, 113 (07) :1581-1588

[3]

Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab [J].

Berthod, Gregoire ;

Lazor, Romain ;

Letovanec, Igor ;

Romano, Emanuela ;

Noirez, Leslie ;

Stalder, Jessica Mazza ;

Speiser, Daniel E. ;

Peters, Solange ;

Michielin, Olivier .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :E156-E159

[4]

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[5]

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[6]

Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti-CTLA-4 Antibody Therapy [J].

Bronstein, Yulia ;

Ng, Chaan S. ;

Hwu, Patrick ;

Hwu, Wen-Jen .

AMERICAN JOURNAL OF ROENTGENOLOGY, 2011, 197 (06) :W992-W1000

[7]

CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition [J].

Buchbinder, Elizabeth I. ;

Desai, Anupam .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (01) :98-106

[8]

Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials [J].

Costa, Ricardo ;

Carneiro, Benedito A. ;

Agulnik, Mark ;

Rademaker, Alfred W. ;

Pai, Sachin G. ;

Villaflor, Victoria M. ;

Cristofanilli, Massimo ;

Sosman, Jeffrey A. ;

Giles, Francis J. .

ONCOTARGET, 2017, 8 (05) :8910-8920

[9]

Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma [J].

Danlos, Francois-Xavier ;

Pages, Cecile ;

Baroudjian, Barouyr ;

Vercellino, Laetitia ;

Battistella, Maxime ;

Mimoun, Maurice ;

Jebali, Majdi ;

Bagot, Martine ;

Tazi, Abdellatif ;

Lebbe, Celeste .

CHEST, 2016, 149 (05) :E133-E136

[10]

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade [J].

Downey, Stephanie G. ;

Klapper, Jacob A. ;

Smith, Franz O. ;

Yang, James C. ;

Sherry, Richard M. ;

Royal, Richard E. ;

Kammula, Udai S. ;

Hughes, Marybeth S. ;

Allen, Tamika E. ;

Levy, Catherine L. ;

Yellin, Michael ;

Nich, Geoffrey ;

White, Donald E. ;

Steinberg, Seth M. ;

Rosenberg, Steven A. .

CLINICAL CANCER RESEARCH, 2007, 13 (22) :6681-6688

← 1 2 3 4 5 6 →